MiMedx Group Inc (MDXG)vsBeiGene, Ltd. (ONC)
MDXG
MiMedx Group Inc
$4.10
-0.73%
HEALTHCARE · Cap: $612.09M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1176% more annual revenue ($5.34B vs $418.63M). MDXG leads profitability with a 11.6% profit margin vs 5.4%. MDXG trades at a lower P/E of 12.9x. MDXG earns a higher WallStSmart Score of 72/100 (B).
MDXG
Strong Buy72
out of 100
Grade: B
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$14.98
Current Price
$4.10
$10.88 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Return on Equity, P/E Ratio. Revenue growth of 27.1% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
MDXG profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.60 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (72/100 vs 42/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?